Published Technical Disclosure Archive

Evolutionary Ubiquitin Ligase-Based Protein Degradation Platform

Publication ID: 24-11857519_0010_PTD
Published: October 28, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Evolutionary Ubiquitin Ligase-Based Protein Degradation Platform,” Published Technical Disclosure No. 24-11857519_0010_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857519_0010_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,519.

Summary of the Inventive Concept

A next-generation protein degradation platform that leverages adaptive E3 ubiquitin ligase proteins, machine learning algorithms, and microRNA-programmed nanoparticles to provide a universal solution for targeting disease-associated proteins

Background and Problem Solved

The original patent, 'Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide', has limitations in its scope and specificity. The new inventive concept addresses these limitations by introducing a highly adaptable and targeted protein degradation platform that can evolve to address a wide range of disease-associated proteins

Detailed Description of the Inventive Concept

The new platform comprises a novel, adaptive E3 ubiquitin ligase protein that can be engineered to target specific disease-associated proteins. This is achieved through the use of machine learning algorithms that predict the efficacy of the ubiquitin ligase-based protein degradation platform against target proteins, generating optimized bifunctional or chimeric constructs for use in the platform. The platform also utilizes microRNA-programmed nanoparticles to deliver these constructs to specific cells or tissues, enabling targeted protein degradation and minimizing off-target effects

Novelty and Inventive Step

The new claims introduce several novel and non-obvious features, including the use of adaptive E3 ubiquitin ligase proteins, machine learning algorithms for optimizing protein degradation, and microRNA-programmed nanoparticles for targeted delivery. These features provide a significant improvement over the original patent, enabling a universal protein degradation solution

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different types of nanoparticles or delivery mechanisms, or the integration of additional machine learning algorithms to further optimize protein degradation. Variations could also include the development of novel E3 ubiquitin ligase proteins with improved specificity or activity

Potential Commercial Applications and Market

The evolutionary ubiquitin ligase-based protein degradation platform has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of cancer, neurodegenerative diseases, and rare genetic disorders. The platform's adaptability and targeting capabilities make it an attractive solution for addressing a wide range of disease-associated proteins

CPC Classifications

SectionClassGroup
A A61 A61K31/166
A A61 A61K31/351
A A61 A61K31/405
A A61 A61K38/45
A A61 A61K47/545
A A61 A61K47/55
A A61 A61K47/555
A A61 A61P35/00
C C07 C07D401/14
C C07 C07D405/12
C C07 C07D405/14
C C07 C07D409/14
C C07 C07D417/14
C C07 C07D471/04
C C12 C12N9/1007
C C12 C12Y201/01043

Field of Art

Pharmaceutical biotechnology, protein engineering, targeted protein degradation, with expertise in molecular biology, medicinal chemistry, and computational design techniques

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in biochemistry or molecular biology, experienced in protein modification, drug discovery, and computational modeling techniques, familiar with ubiquitin-proteasome systems and protein engineering strategies

Obviousness Rationale

A person having ordinary skill would recognize that the PTD represents a predictable extension of the source patent's protein targeting methodology by introducing computational design and adaptive delivery mechanisms. The core concept of targeted protein degradation remains consistent, with the PTD introducing incremental improvements in targeting specificity and delivery efficiency. These variations represent standard evolutionary approaches in protein therapeutic design that would be apparent to a skilled practitioner in the field.

Obvious Combinations & Variations

Source Patent Element
Compounds for targeted protein degradation using ubiquitin ligase mechanisms
PTD Variation
Machine learning algorithms for optimizing protein degradation construct design
Obviousness Reasoning
Computational design of protein therapeutics is a known technique, and applying machine learning to protein engineering represents a predictable optimization strategy within the field
Source Patent Element
Chimeric constructs targeting specific protein interactions
PTD Variation
Adaptive E3 ubiquitin ligase proteins with modular architectures
Obviousness Reasoning
Modular protein design is a standard approach in protein engineering, allowing systematic exploration of binding and functional variations with predictable results
Source Patent Element
Pharmaceutical compositions for protein targeting
PTD Variation
MicroRNA-programmed nanoparticle delivery systems
Obviousness Reasoning
Advanced drug delivery technologies are routinely explored to improve targeting and reduce off-target effects, representing an obvious extension of existing pharmaceutical design principles
Source Patent Element
Chemical linking moieties for protein interaction
PTD Variation
Bifunctional constructs engineered to induce conformational changes in ubiquitin ligases
Obviousness Reasoning
Protein conformational engineering is a known technique for modulating protein function, and would be an obvious approach for enhancing ubiquitination activity
Source Patent Element
Targeted protein degradation methodology
PTD Variation
Universal protein degradation platform with evolving targeting capabilities
Obviousness Reasoning
Creating generalized platforms from specific therapeutic approaches is a standard strategy in biotechnology, representing a predictable technological progression
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857519 and the disclosed variations, a person having ordinary skill in the art would find the claimed protein degradation platform obvious, as the technical modifications represent predictable extensions of existing targeted protein degradation methodologies, utilizing standard computational design, protein engineering, and drug delivery techniques known in the pharmaceutical biotechnology field.

Original Patent Information

Patent NumberUS 11,857,519
TitleCompounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
Assignee(s)Arvinas Operations, Inc.